2 research outputs found
The management of type 2 diabetes with fixedâratio combination insulin degludec/liraglutide (IDegLira) versus basalâbolus therapy (insulin glargine U100 plus insulin aspart): a shortâterm costâeffectiveness analysis in the UK setting
Aim:
To evaluate the costâeffectiveness of IDegLira versus basalâbolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
Methods:
A Microsoft Excel model was used to evaluate the costâutility of IDegLira versus BBT over a 1âyear time horizon. Clinical input data were taken from the treatâtoâtarget DUAL VII trial, conducted in patients unable to achieve adequate glycaemic control (HbA1câ<7.0%) with basal insulin, with IDegLira associated with lower rates of hypoglycaemia and reduced body mass index (BMI) in comparison with BBT, with similar HbA1c reductions. Costs (expressed in GBP) and eventârelated disutilities were taken from published sources. Extensive sensitivity analyses were performed.
Results:
IDegLira was associated with an improvement of 0.05 qualityâadjusted life years (QALYs) versus BBT, due to reductions in nonâsevere hypoglycaemic episodes and BMI with IDegLira. Costs were higher with IDegLira by GBP 303 per patient, leading to an incremental costâeffectiveness ratio (ICER) of GBP 5924 per QALY gained for IDegLira versus BBT. ICERs remained below GBP 20â000 per QALY gained across a range of sensitivity analyses.
Conclusions:
IDegLira is a costâeffective alternative to BBT with insulin glargine U100 plus insulin aspart, providing equivalent glycaemic control with a simpler treatment regimen for patients with type 2 diabetes inadequately controlled on basal insulin in the UK